Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou(Tongji University), Changxuan You(Southern Medical University), L Zhang(Sun Yat-sen University), Yi Luo(Kunming Institute of Botany), Chengping Hu(Central South University), Lei Chen(Zhuzhou Central Hospital), Li Zhang(Gdańsk Medical University), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunhong Hu(Central South University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Jianan Huang(Soochow University), Songwen Zhou(Tongji University), Ming Ye(Shanghai Jiao Tong University), Jifeng Feng(Zhejiang Cancer Hospital), Yiping Zhang(Henan Normal University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Shucai Zhang(Northeastern University), Gongyan Chen(Harbin Medical University), Qingyu Xiu(Second Military Medical University), Shun Lü(Shanghai Jiao Tong University), Jun Ma(Harbin Institute of Petroleum), Shengxiang Ren(Tongji University)
The Lancet Oncology
July 25, 2011
10.1016/s1470-2045(11)70184-x
Cited by 4,098

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k